Vor Biopharma Announces Positive Phase 3 Results for Telitacicept in IgA Nephropathy; Data to Be Presented at ASN Kidney Week 2025
Reuters
Oct 17
Vor Biopharma Announces Positive Phase 3 Results for Telitacicept in IgA Nephropathy; Data to Be Presented at ASN Kidney Week 2025
Vor Biopharma Inc. announced that new clinical data from Stage A of a Phase 3 study in China evaluating telitacicept in adults with IgA nephropathy (IgAN) will be presented as a late-breaking oral presentation at the American Society of Nephrology's Kidney Week 2025, scheduled for November 5-9, 2025, in Houston, Texas. The study, sponsored by RemeGen Co., Ltd, reported topline results in August, showing that telitacicept achieved the primary endpoint by reducing proteinuria, with a 55% reduction in 24-hour urine protein-to-creatinine ratio at 39 weeks compared with placebo (p<0.0001). Telitacicept also demonstrated a favorable safety profile. Full results from Part A of the study will be presented at the conference. RemeGen has submitted a Biologics License Application to the National Medical Products Administration in China for this indication.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vor Biopharma Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9547123-en) on October 17, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.